Global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects the brain, leading to cognitive decline and memory loss. It is the most common cause of dementia, a syndrome characterized by a decline in cognitive function that interferes with daily life. Alzheimer's disease is named after Dr. Alois Alzheimer, who first identified the condition in 1906.

Currently, there is not significant leading product on the market, and the competition landscape for AD diagnostic reagents is relatively good. In the future, with the approval of more accurate mass spectrometry and other kits, the application of combined detection methods, and the approval of more AD treatment drugs, the AD diagnostic industry has huge development potential, and the market space may further expand.

The cerebrospinal fluid (CSF) biomarkers, that were first developed by Fujirebio more than 25 years ago, have evolved over time from research biomarkers into specialized diagnostic testing tools, and from manual usage by early adopters to a widespread implementation in fully automated routine testing today.

Diagnosis for Alzheimer’s disease using CSF samples allows the detection of four proteins: two forms of amyloid (Aβ1-42 and Aβ1-40) proteins and two forms of Tau (Total Tau and phospho-Tau) proteins. If a patient has Alzheimer’s disease, then these proteins will be present in abnormally low (Aβ1-42 and Aβ1-42/Aβ1-40 ratio) and high (Total Tau and phospho-Tau) levels. The Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio will even be low long before the symptoms of the disease start to show.

In the clinical community today, there are high hopes for the use of blood-based testing for even simpler and potentially more widespread testing for Alzheimer’s disease in clinical routine.

According to our (Global Info Research) latest study, the global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market size was valued at US$ 35.6 million in 2023 and is forecast to a readjusted size of USD 125 million by 2030 with a CAGR of 18.2% during review period.

Rising Prevalence of Alzheimer's Disease: The increasing global prevalence of Alzheimer's disease is a significant driver for the development of early diagnosis kits. As the aging population grows, the demand for reliable diagnostic tools for early detection becomes more critical.

Focus on Early Intervention and Treatment: With the recognition that early intervention and treatment may have a more significant impact on disease progression, there is a growing emphasis on the development of tools that enable early diagnosis. This shift in therapeutic strategies encourages investment in early detection technologies.

Technological Innovations in Diagnostics: Advances in diagnostic technologies, including imaging techniques, molecular diagnostics, and blood-based assays, contribute to the development of more sophisticated and precise early diagnosis kits. These innovations enhance the sensitivity and specificity of diagnostic tools.

This report is a detailed and comprehensive analysis for global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030

Global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030

Global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030

Global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Fujirebio, Quanterix, People Bio, Easund Bio-tech and Pharmakea, MagQu, Solgent, Sysmex, Immuno-Biological Laboratories, Shenzhen Anqun Bioengineering, Amoneta Diagnostics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Magnetic Particle Chemiluminescence Methods
Enzyme-linked Immunoassay Methods
Chemiluminescence Immunoassay Methods
Dry Fluorescence Immunochromatography Methods
Others

Market segment by Application
Clinical Diagnosis
Research

Major players covered
Fujirebio
Quanterix
People Bio
Easund Bio-tech and Pharmakea
MagQu
Solgent
Sysmex
Immuno-Biological Laboratories
Shenzhen Anqun Bioengineering
Amoneta Diagnostics

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease, with price, sales quantity, revenue, and global market share of Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease from 2019 to 2024.

Chapter 3, the Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease.

Chapter 14 and 15, to describe Blood-based Detection Kit for Early Diagnosis of Alzheimer's Disease sales channel, distributors, customers, research findings and conclusion.